To request a Grand Rounds CLICK HERE

Would you like to host a complimentary Grand Rounds presentation for your hematologists, oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other allied health professionals of the hematology/oncology team. This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.

Learning Objectives
•Outline the role of the B-cell receptor (BCR) pathway in the development of B-cell malignancies and identify enzymes downstream of the BCR that can serve as therapeutic agents.  
•Examine recent, top-line trial data for novel agents in the treatment of B-cell malignancies, including, BTK inhibitors, PI3K inhibitors, and BCL2 inhibitors.
•Analyze the most recent national guideline recommendations for the treatment of various B-cell malignancies and discuss the emerging role of novel agents into these treatment paradigms.
•Using a case-based approach, assess key issues in therapy selection, optimizing the use of novel therapies, managing adverse events, increasing patient adherence, and improving communication with both patients and with other members of the oncology care team.

5 min -  Welcome and Introductions
10 min - The BCR Pathway: A Key Target in B-cell Malignancies 
25 min - Exploring Contemporary Treatment Approaches: Novel Agents in B-cell Malignancies 
15 min - Putting it into Practice: Patient Cases and Practical Strategies for Interprofessional Oncology Care Team
5 min -  Conclusion and Q&A

Matthew S. Davids, MD
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

1-hour presentation providing up to 1.0 ACCME/ANCC/ACPE credit provided by the University of Cincinnati 

Supported by independent educational grants from Janssen and AstraZeneca.